Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; PMV Pharma) today announced a partnership to develop Foundation Medicines tissue-based comprehensive genomic profiling test...